Drugs in Dev. Oncology
Phase III
Spain 
Lead Product(s) : Clodronic Acid Disodium Salt
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MAFTEST® adjuvant bisphosphonates therapy Bonefos, (clodronate disodium) result showed significant efficacy and reduce risk of death at 5 and 10 years by 26% and 23% respectively in early-stage (stage I-III) breast cancer patients compared with current ...
Product Name : Bonefos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 14, 2022
Lead Product(s) : Clodronic Acid Disodium Salt
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lurbinectedin,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Jazz Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zepzelca (lurbinectedin) is a DNA-negative allosteric modulator. It is being developed for the treatment of patients with relapsed small cell lung cancer.
Product Name : Zepzelca
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 13, 2021
Lead Product(s) : Lurbinectedin,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Jazz Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Megapharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
PharmaMar and Megapharm sign a licensing agreement for lurbinectedin in Israel
Details : This new agreement will allow lurbinectedin to reach the Israeli market, if approved, in the hands of one of the leading companies in the field of oncology in this country.
Product Name : Zepzelca
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
November 05, 2020
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Megapharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Jazz Pharmaceuticals
Deal Size : $1,000.0 million
Deal Type : Licensing Agreement
Details : PharmaMar & Jazz signed an exclusive license agreement for U.S. rights to lurbinectedin, the effectiveness of which was subject to the expiration or early termination of the applicable HSR waiting period.
Product Name : Zepzelca
Product Type : Cytotoxic Drug
Upfront Cash : $200.0 million
January 22, 2020
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Jazz Pharmaceuticals
Deal Size : $1,000.0 million
Deal Type : Licensing Agreement
Reset All
